Our track record
Since 2019, we have completed 70+ biotechnology strategy reviews, undertaken 20+ sell-side transactions & 40+ buy-side projects.
Whilst much of our work in the M&A space is confidential, a selection of our completed projects are listed below.
We support a broad set of transactions, including:
- Mergers
- Acquisitions
- Management-led buyouts
- Disposals (assets and stock)
- Specialist Commercial Due Diligence (CDD)
We have a proprietary database of sellers globally, covering manufacturers, distributors and hybrid resellers.
| European life science distribution companies | Veterinary diagnostics distributors |
| IVD Reagents and raw materials | Life science reagent distributors |
| Manufactures of antibodies, kits and proteins | IVD reagent and raw materials |
Recent Transactions
Pivotal Scientific advises Antibody BCN on its sale to CliniSciences
CliniSciences adds to its portfolio of companies Pivotal Scientific Limited (PSL) is pleased to announce its assistance in the sale of Spanish based Biotechnology company AbBcn…
LifeSpan BioSciences, Inc. announces the acquisition of Everest Biotech
Release Date: July 31st, 2019 Seattle, Washington State, USA– June 2019 – LifeSpan BioSciences (LSBio), a leading provider of antibodies and life science research reagents…
Pivotal Scientific advises EastCoast Bio on its sale to Medix Biochemica
A successful transaction benefitting both parties. Pivotal Scientific is delighted to announce its assistance in the sale of US-based biotech firm EastCoast Bio to the…
- « Previous
- 1
- 2